A recent illumina run analysis showed that the majority of our sequences were contaminated with 16S rRNA. Prior to dscDNA we used a rRNA depletion method using the RiboZero Bacteria Magnetic kit. We ran our samples on a Pico Chip and saw our sample had lost the peaks from 16S and 23S so the depletion step works. If contamination occurred it must have been either during dscDNA construction or prior to the illumina run. Could you help me determine which step might have introduced contaminants? In my attachment you will see the dscDNA run on a high sensitivity chip. Does this look fine? Please ignore the empty lanes.
-
-
Hi vanillasky,
In my experience, you should see a one and only smooth band in your dscDNA preparation when running a DNA HS chip… I can't see that in the file you attached. So I do not recommend you to proceed with sequencing for this sample.
I also think that after RIboZero treatment, running a NanoChip is enough and better than the Pico one. -
Thank you for the reply. Unfortunately, I did end up sequencing and found that there were contaminants in there. I was never able to get this particular sample to work with the library preparation kit I used. I have talked to Agilent tech support in the past and they recommended the pico chip for mRNA analysis (which was my target). They told me the nanochip is good for quantitation vs the picochip. Also, the concentrations of my sample are so low that working with the picochip is better. Anyway, thank you for your post, I will keep this in mind if I ever work on this again.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment